- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01545219
A Study of a Prebiotic, a Probiotic and a Synbiotic Upon the Gut Microbiota and Immune Response of Healthy Volunteers (XOS)
A Double-blind, Placebo-controlled, Randomized Crossover Study to Determine the Effects of Xylooligosaccharides (XOS), B. Lactis (BI07) and XOS + BI07 Upon the Gut Microbiota and Immune Response of Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this study is to determine the effect of XOS (administered at 8g/day), B. lactis BI07 (administered at 109 CFU/day) and the synbiotic combination of both (8g/day XOS and 109 CFU/day B. lactis BI07) on the human gut microbiota.
A double-blind, placebo-controlled, randomized crossover study will be conducted in 44 healthy volunteers. The placebo will be maltodextrin (a food grade ingredient, administered at 8g/day).
Changes in the gut microbiota will be determined by measuring bacterial population levels in human faeces using fluorescence in situ hybridisation (FISH) with 16S rRNA targeted oligonucleotide probes. Concentrations of short chain fatty acids (SCFA) will be quantified using gas chromatography (GC).
In addition to analyses performed on the samples at the University of Reading, analyses on microbial metabolites and selected members of the microbiota will also be performed at Danisco Finland, Kantvik. University of Reading will therefore provide Danisco Kantvik with faecal samples of appropriate size.
The secondary objective of this study is to examine the effects of XOS (8g/day), B. lactis BI07 (109 CFU/day) and the synbiotic (8g/day of XOS and 109 CFU/day of B. lactis BI07) on bowel function, immune function and plasma lipids in 44 healthy volunteers. This will be achieved using volunteer diaries of bowel function and mood, and by investigating total plasma lipids, mucosal immunity (salivary and faecal IgA), total leukocyte numbers, expression of cell surface markers on immune cells to identify cell subsets and activation markers, production of inflammatory markers by whole blood cultures, plasma chemokines, phagocytosis and oxidative burst by monocytes and granulocytes, plasma/serum immunoglobulins, acute phase proteins, complement proteins and soluble adhesion molecules.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Berkshire
-
Reading, Berkshire, United Kingdom, RG6 6AP
- University of Reading
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- signed consent form
- age 25-65 years
- body mass index 20-30 inclusive
- good general health as determined by medical questionnaires
- additional inclusion criteria: as far as possible, target volunteer group will have mild constipation (bowel movement of less than 1/day, hard stool consistency)
Exclusion Criteria:
• Evidence of physical or mental disease or planned major surgery, which might limit participation in or completion of the study
- History of drug abuse, including alcohol
- Severe allergy or a history of severe abnormal drug reaction
- Participation in experimental drug trial within four weeks prior to study
- Participation in prebiotics or laxative trial within the previous three months
- Use of antibiotics within the previous six months
- Chronic constipation, diarrhoea or other chronic gastro-intestinal complaint
- Intake of other prebiotics or probiotics, drugs active on gastrointestinal motility, or a laxative of any class for four weeks prior to study
- Use of prescribed medication
- Regular use of aspirin or other anti-inflammatory drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
8g/day maltodextrin
|
Experimental: Probiotic
|
10^9 CFU B. lactis / day
|
Experimental: Prebiotic
|
8g/day xylo-oligosaccharide
|
Experimental: Synbiotic
|
8g/day xylo-oligosaccharide + 10^9 CFU Bi-07
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes to the gut microbiota
Time Frame: 7 months
|
Changes in faecal bacterial populations will be assessed through the use of FISH with molecular probes targeting 16S rRNA genes.
Genotypic probes targeting the predominant components of the gut microflora (Bacteroides, Bifidobacterium, Clostridium, Lactobacillus, Eubacterium, Atopobacterium, Streptococcus, sulphate reducing bacteria and enterobacteria) and total bacteria will be tagged with fluorescent markers such that quantifiable changes may be determined.
Concentrations of short chain fatty acids (SCFA) will be quantified using gas chromatography (GC).
|
7 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bowel function, immune function and plasma lipids
Time Frame: 7 months
|
This will be achieved using volunteer diaries of bowel function and mood, and by investigating total plasma lipids, mucosal immunity (salivary and faecal IgA), total leukocyte numbers, expression of cell surface markers on immune cells to identify cell subsets and activation markers, production of inflammatory markers by whole blood cultures, plasma chemokines, phagocytosis and oxidative burst by monocytes and granulocytes, plasma/serum immunoglobulins, acute phase proteins, complement proteins and soluble adhesion molecules.
|
7 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Glenn R Gibson, BSc, PhD, University of Reading
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 08/38
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gut Microbiota
-
Shanghai 10th People's HospitalRecruitingGut MicrobiotaChina
-
University of California, DavisCompletedGut MicrobiotaUnited States
-
TCI Co., Ltd.Completed
-
University of AberdeenNHS GrampianRecruitingGut MicrobiotaUnited Kingdom
-
University of ReadingCompleted
-
Biofortis, Merieux NutriSciencesLonza Inc.CompletedGut MicrobiotaUnited States
-
Kosin University Gospel HospitalCompleted
-
University of California, BerkeleyCompleted
-
Pennington Biomedical Research CenterWithdrawnGut Microbiota
-
University Hospital, Clermont-FerrandNeuromed IRCCS; Centre de Recherche en Nutrition Humaine d'Auvergne; Mediterranean...Unknown
Clinical Trials on Prebiotic
-
Beneo-InstituteUniversity of ReadingCompletedMoodUnited Kingdom
-
Centros de Investigación de Nutrición y SaludNutribioticaCompletedFunctional ConstipationSpain
-
University of Maryland, BaltimoreNational Center for Complementary and Integrative Health (NCCIH)RecruitingSchizophrenia | Schizoaffective DisorderUnited States
-
University of CalgaryGeneral MillsCompleted
-
Rush University Medical CenterCures Within ReachCompletedPost Traumatic Stress DisorderUnited States
-
Hospital Universitari Vall d'Hebron Research InstituteCompleted
-
University of ChicagoRecruiting
-
Maastricht UniversityRecruiting
-
Rush University Medical CenterCompleted
-
Universitaire Ziekenhuizen KU LeuvenWithdrawn